Passage Bio, Inc., a genetic medicines company focused on rare, monogenic central nervous system (CNS) disorders, and Catalent, began manufacturing operations to support adeno-associated virus (AAV) production for Passage Bio’s lead gene therapy product candidates for the treatment of rare monogenic CNS disorders. This follows the recent completion of construction and cGMP qualification of a dedicated manufacturing suite for Passage Bio at Catalent Cell & Gene Therapy’s facility in Harmans, ...